Oct 23, 2019
Allievex Completes Series A Financing Led by Pappas Capital and Novo Holdings
Feb 04, 2019
BioMarin Announces 14 Presentations at 15th Annual WORLDSymposium(TM) 2019
Nov 05, 2018
REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
Aug 17, 2018
2018 Mucopolysaccharidosis Disorders Drug Development Pipeline Review
Aug 10, 2018
First Patient Dosed in Phase 1/2 Study Evaluating SOBI003 for Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)
Aug 02, 2018
ArmaGen Receives U.S. Orphan Drug Designation for AGT-184
Jun 05, 2018
Mucopolysaccharidosis III (Sanfilippo syndrome) Pipeline Analysis 2018: 12 Drugs Currently in Different Phases of Development
May 15, 2018
Shire Recognizes MPS Awareness Day 2018 with Digital Campaign and Global Events Focused on Increasing Diseases Awareness
Feb 07, 2018
BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at WORLDSymposium(TM) 2018
Jan 23, 2018
FDA Accepts Investigational New Drug Application and Grants Fast Track Status for SOBI003 for the Treatment of MPS IIIA
Sep 19, 2017
Jonah's Just Begun-Foundation to Cure Sanfilippo Inc. (JJB) Announces Awareness Campaign: Mission Hide and Help
Sep 06, 2017
BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017
Jun 15, 2017
Mucopolysaccharidosis III - Pipeline Review, H1 2017